Drug-induced myopathies are a common cause of muscle pain, and the range of drugs that can cause muscle side effects is constantly expanding. In this article, the authors comprehensively discuss the diagnostic and therapeutic process in patients with myalgia, and present the spectrum of drug-induced myopathies. The review provides a detailed analysis of the literature on the incidence of myopathy during treatment with hypolipemic drugs, beta-blockers, amiodarone, colchicine, glucocorticosteroids, antimalarials, cyclosporine, zidovudine, and checkpoint inhibitors, a group of drugs increasingly used in the treatment of malignancies. The article considers the clinical course of the different types of myopathies, their pathogenesis, histopathological features, and treatment methods of these disorders. The aim of this paper is to gather from the latest available literature up-to-date information on the course, pathophysiology, and therapeutic options of drug-induced myopathies, to systematize the knowledge of drug-induced myopathies and to draw the attention of internists to the fact that these clinical issues are an important therapeutic problem.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11117896 | PMC |
| http://dx.doi.org/10.3390/biomedicines12050987 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Daidzein improves muscle atrophy caused by lovastatin by regulating the AMPK/FOXO3a axis.
Chin Med
December 2024
State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Background: Lovastatin, the main lipid-lowering component in red yeast rice, is a golden anti-lipid drug, but its long-term application is continuously challenged by potential skeletal muscle atrophy. Daidzein, an isoflavone derived from soybeans and many Chinese medicines, shows therapeutic potential in treating muscle-related diseases and metabolic disorders. However, whether daidzein can improve lovastatin-induced muscle atrophy and the specific mechanism needs to further study.
View Article and Find Full Text PDFBone marrow-derived dendritic cells play a role in attenuating inflammation on Bothrops jararacussu venom muscle damage.
J Biotechnol
November 2024
Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ Rondônia, Porto Velho, RO, Brazil; Departamento de Medicina, Universidade Federal de Rondônia, UNIR, Porto Velho, RO, Brazil. Electronic address:
The immune system is regulated by dendritic cells (DCs), which are highly specialized cells for presenting antigens. They are thought of as natural sentinels that start the immune response triggered by naive T cells against invasive infections. DCs participate in the initial stage of muscle damage in conjunction with monocytes, macrophages, and myogenic cells.
View Article and Find Full Text PDFLipid storage myopathy associated with sertraline treatment is an acquired mitochondrial disorder with respiratory chain deficiency.
Acta Neuropathol
November 2024
Department of Laboratory Medicine, University of Gothenburg, Gothenburg, Sweden.
Lipid storage myopathies are considered inborn errors of metabolism affecting the fatty acid metabolism and leading to accumulation of lipid droplets in the cytoplasm of muscle fibers. Specific diagnosis is based on investigation of organic aids in urine, acylcarnitines in blood and genetic testing. An acquired lipid storage myopathy in patients treated with the antidepressant drug sertraline, a serotonin reuptake inhibitor, has recently emerged as a new tentative differential diagnosis.
View Article and Find Full Text PDF[Not Available].
Ugeskr Laeger
October 2024
Afdeling for Hjertesygdomme, Sygehus Sønderjylland, Aabenraa.
Statin-induced immune-mediated necrotising myopathy (IMNM) is a rare complication associated with statin use. IMNM is classified as one of the inflammatory myopathies characterised by myalgia and elevated serum creatine kinase (CK) levels. In this case report, we present a 58-year-old woman who developed IMNM secondary to atorvastatin use.
View Article and Find Full Text PDFImmune Checkpoint Inhibitor Myopathy: The Double-Edged Sword of Cancer Immunotherapy.
Neurology
December 2024
From the Division of Neurology (G.B.), Department of Medicine, University of Alberta, Edmonton, Canada; Muscle Disease Section (I.P.-F., A.L.M.), National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda; Department of Neurology (I.P.-F., A.L.M.), Johns Hopkins University School of Medicine, Baltimore, MD; and Department of Neurology (T.L.), Mayo Clinic, Rochester, MN.
Immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of several malignancies, with improved survival. These monoclonal antibodies target immune checkpoints, including cytotoxic T-lymphocyte-associated protein 4 (ipilimumab and tremelimumab), programmed death 1 (nivolumab, pembrolizumab, cemiplimab, and dostarlimab), programmed death ligand 1 (atezolizumab, avelumab, and durvalumab), and lymphocyte activation gene 3 (relatlimab), and effectively augment the immune response against tumor cells. Releasing the brakes on the immune system has consequences, however, in the form of immune-related adverse events (irAEs), which may affect any organ.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!